New data demonstrates long-term skin clearance in patients with moderate to severe plaque psoriasis treated with Janssen’s Tremfya (guselkumab).
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving Tremfya (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.1
Findings from the study also demonstrated that a vast majority of patients originally randomized to guselkumab, but withdrawn from treatment at week 28, regained a PASI 90 response within six months of initiating guselkumab retreatment.1
The long-term findings from the Phase III VOYAGE 2 study were presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego during a late-breaking abstract session at 1 p.m. PST on Saturday February 17.
“The longer-term data from VOYAGE 2 shows promising results for guselkumab as both a continuous, long-term treatment for moderate to severe plaque psoriasis, and as an option for patients who have been withdrawn from therapy and retreated,” said study investigator Prof. Kristian Reich, M.D. of Dermatologikum Berlin and SCIderm Research Institute in Hamburg, Germany. “These data provide important information to dermatologists should they need to interrupt treatment with guselkumab for a period of time, as the findings demonstrate guselkumab quickly and robustly re-established a PASI 90 response within six months.”
Results from the trial demonstrated that among patients who achieved a PASI 90 response at week 28 with guselkumab, 86 percent who continued receiving guselkumab maintained a PASI 90 response through week 72, while only 11.5 percent of patients who were withdrawn from treatment maintained a PASI 90 response.1
Of the 173 patients who were withdrawn from receiving guselkumab, 87.6 percent achieved a PASI 90 response within six months of commencing retreatment.1
Adverse events reported in at least five percent of guselkumab-treated patients during the first 16 weeks of the VOYAGE 1 and 2 trials included: Nasopharyngitis, upper respiratory tract infection, injection site erythema, headache, arthralgia, pruritus, and back pain.2,3 No new safety signals were observed with continuous treatment with guselkumab through week 100.4
__________________________________________________________
References:
1 Gordon K, Armstrong A, et al. American Academy of Dermatology (AAD) 2018 Annual Meeting 16–20 February 2018; San Francisco, USA, ID #6748.
2 Reich K and Armstrong AW, et al. J Am Acad Dermatol 2017;76(3):418–31.
3 Blauvelt A, Papp KA, et al. J Am Acad Dermatol 2017;76(3):405–17.
4 Reich K, Papp K, et al. 8th International Congress of Psoriasis from Gene to Clinic 30 November–2 December 2017; London, UK, ID #75.
(Source: Janssen Pharmaceuticals, Inc.)
Filed Under: Drug Discovery
